PEDIATRICS Vol. 104 No. 6 December 1999, pp. 1258-1263

Prophylaxis Against Early Adrenal Insufficiency to Prevent Chronic Lung Disease in Premature Infants

Received Feb 15, 1999; accepted May 26, 1999.

Kristi L. Watterberg^*, Jeffrey S. Gerdes^§, Kathleen L. Gifford^*, and Hung-Mo Lin

From the ^* Departments of Pediatrics and  Health Evaluation Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and the ^§ Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

Background.  Many extremely low birth weight infants (<1000 g) show biochemical evidence of adrenal insufficiency in the first week of life, correlating with subsequent development of chronic lung disease (CLD).

Methods.  We conducted a randomized, double-masked, placebo-controlled pilot study to test whether early treatment with low-dose hydrocortisone for 12 days (1 mg/kg/day for 9 days followed by .5 mg/kg/day for 3 days), begun before 48 hours of life, would increase the likelihood of survival without CLD.

Results.  Forty patients were enrolled at two centers. Birth weight and gestation were similar for treatment and placebo groups: 732 ± 135 g versus 770 ± 135 g and 25.2 ± 1.3 weeks versus 25.4 ± 1.5 weeks. More infants treated with hydrocortisone achieved study success, defined as survival without supplemental oxygen at 36 weeks' postconception (12/20 [60%] vs 7/20 [35%]). Lower birth weight, histologic chorioamnionitis, and preeclampsia were significant risk factors, whereas study center, prenatal steroids, sex, and ethnicity were not significant. Hydrocortisone treatment decreased days on >40% oxygen, days on >25% oxygen, days on ventilator, and oxygen at discharge. Among infants exposed to chorioamnionitis, hydrocortisone treatment also was associated with increased enteral intake during the first month of life and with increased weight at 36 weeks' postconception. Five treated infants and 6 placebo infants developed sepsis; 3 in each group died.

Conclusions.  First, early treatment with low-dose hydrocortisone in this population of extremely low birth weight infants increased the likelihood of survival without CLD. Second, the benefit was particularly apparent in infants with chorioamnionitis. Third, a larger multicenter trial is needed to verify the primary outcome and to better evaluate risks and benefits.  Key words:  chronic lung disease, bronchopulmonary dysplasia, premature infant, adrenal function, hydrocortisone, chorioamnionitis.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. O'Mara, P. Gal, J L. RansomMD, J. E WimmerMD Jr, R. Q CarlosMD, M. A. V. DimaguilaMD, C. DavonzoMD, and M. SmithMD Successful Use of Dexmedetomidine for Sedation in a 24-Week Gestational Age Neonate Ann. Pharmacother., October 1, 2009; 43(10): 1707 - 1713. [Abstract] [Full Text] [PDF]

				W. Lenney, A. L. Boner, L. Bont, A. Bush, K-H. Carlsen, E. Eber, B. Fauroux, M. Gotz, A. Greenough, J. Grigg, et al. Medicines used in respiratory diseases only seen in children Eur. Respir. J., September 1, 2009; 34(3): 531 - 551. [Abstract] [Full Text] [PDF]

				S. W. Aucott, K. L. Watterberg, M. L. Shaffer, P. K. Donohue, and for the PROPHET Study Group Do Cortisol Concentrations Predict Short-Term Outcomes in Extremely Low Birth Weight Infants? Pediatrics, October 1, 2008; 122(4): 775 - 781. [Abstract] [Full Text] [PDF]

				E. D. Bruder, J. K. Taylor, K. J. Kamer, and H. Raff Development of the ACTH and corticosterone response to acute hypoxia in the neonatal rat Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1195 - R1203. [Abstract] [Full Text] [PDF]

				R. Karemaker, A. Kavelaars, M. ter Wolbeek, M. Tersteeg-Kamperman, W. Baerts, S. Veen, J. F. Samsom, G. H. A. Visser, F. van Bel, and C. J. Heijnen Neonatal Dexamethasone Treatment for Chronic Lung Disease of Prematurity Alters the Hypothalamus-Pituitary-Adrenal Axis and Immune System Activity at School Age Pediatrics, April 1, 2008; 121(4): e870 - e878. [Abstract] [Full Text] [PDF]

				K J Rademaker, L S de Vries, C S P M Uiterwaal, F Groenendaal, D E Grobbee, and F van Bel Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2008; 93(1): F58 - F63. [Abstract] [Full Text] [PDF]

				K. L. Watterberg, M. L. Shaffer, M. J. Mishefske, C. L. Leach, M. C. Mammel, R. J. Couser, S. Abbasi, C. H. Cole, S. W. Aucott, E. H. Thilo, et al. Growth and Neurodevelopmental Outcomes After Early Low-Dose Hydrocortisone Treatment in Extremely Low Birth Weight Infants Pediatrics, July 1, 2007; 120(1): 40 - 48. [Abstract] [Full Text] [PDF]

				E S Shinwell, L Lerner-Geva, A Lusky, B Reichman, and in collaboration with the Israel Neonatal Network Less postnatal steroids, more bronchopulmonary dysplasia: a population-based study in very low birthweight infants Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2007; 92(1): F30 - F33. [Abstract] [Full Text] [PDF]

				M. Hallman, O. Peltoniemi, and T. Saarela Early Neonatal Hydrocortisone: Study Rather Than Treat Pediatrics, December 1, 2006; 118(6): 2540 - 2542. [Full Text] [PDF]

				C. J. Fernandes and Y. R. Johnson Reopening the debate on corticosteroids: to the editor. Pediatrics, June 1, 2006; 117(6): 2321 - 2322. [Full Text] [PDF]

				N. N. Finer, R. J. Powers, C.-h. S. Ou, D. Durand, D. Wirtschafter, J. B. Gould, and for the California Perinatal Quality Care Collabor Prospective Evaluation of Postnatal Steroid Administration: A 1-Year Experience From the California Perinatal Quality Care Collaborative Pediatrics, March 1, 2006; 117(3): 704 - 713. [Abstract] [Full Text] [PDF]

				R. A. Ehrenkranz, M. C. Walsh, B. R. Vohr, A. H. Jobe, L. L. Wright, A. A. Fanaroff, L. A. Wrage, K. Poole, and for the National Institutes of Child Health and Hu Validation of the National Institutes of Health Consensus Definition of Bronchopulmonary Dysplasia Pediatrics, December 1, 2005; 116(6): 1353 - 1360. [Abstract] [Full Text] [PDF]

				M. Heckmann, M. F. Hartmann, B. Kampschulte, H. Gack, R.-H. Bodeker, L. Gortner, and S. A. Wudy Cortisol Production Rates in Preterm Infants in Relation to Growth and Illness: A Noninvasive Prospective Study Using Gas Chromatography-Mass Spectrometry J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5737 - 5742. [Abstract] [Full Text] [PDF]

				R. A. K. Jones and on behalf of the Collaborative Dexamethasone Trial Randomized, Controlled Trial of Dexamethasone in Neonatal Chronic Lung Disease: 13- to 17-Year Follow-up Study: I. Neurologic, Psychological, and Educational Outcomes Pediatrics, August 1, 2005; 116(2): 370 - 378. [Abstract] [Full Text] [PDF]

				G. A. Lodygensky, K. Rademaker, S. Zimine, M. Gex-Fabry, A. F. Lieftink, F. Lazeyras, F. Groenendaal, L. S. de Vries, and P. S. Huppi Structural and Functional Brain Development After Hydrocortisone Treatment for Neonatal Chronic Lung Disease Pediatrics, July 1, 2005; 116(1): 1 - 7. [Abstract] [Full Text] [PDF]

				J. J. Volpe Encephalopathy of Prematurity Includes Neuronal Abnormalities Pediatrics, July 1, 2005; 116(1): 221 - 225. [Full Text] [PDF]

				L. W. Doyle, H. L. Halliday, R. A. Ehrenkranz, P. G. Davis, and J. C. Sinclair Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease Pediatrics, March 1, 2005; 115(3): 655 - 661. [Abstract] [Full Text] [PDF]

				K. L. Watterberg, J. S. Gerdes, C. H. Cole, S. W. Aucott, E. H. Thilo, M. C. Mammel, R. J. Couser, J. S. Garland, H. J. Rozycki, C. L. Leach, et al. Prophylaxis of Early Adrenal Insufficiency to Prevent Bronchopulmonary Dysplasia: A Multicenter Trial Pediatrics, December 1, 2004; 114(6): 1649 - 1657. [Abstract] [Full Text] [PDF]

				E. Kajantie, T. Raivio, O. a. Janne, P. Hovi, L. Dunkel, and S. Andersson Circulating Glucocorticoid Bioactivity in the Preterm Newborn after Antenatal Betamethasone Treatment J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3999 - 4003. [Abstract] [Full Text] [PDF]

				A. H. Jobe Postnatal Corticosteroids for Preterm Infants -- Do What We Say, Not What We Do N. Engl. J. Med., March 25, 2004; 350(13): 1349 - 1351. [Full Text] [PDF]

				O Baud Postnatal steroid treatment and brain development Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2004; 89(2): F96 - F100. [Abstract] [Full Text] [PDF]

				E S Shinwell, M Karplus, D Bader, S Dollberg, I Gur, Z Weintraub, S Arnon, E Gottfreid, A Zaritsky, I R Makhoul, et al. Neonatologists are using much less dexamethasone Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2003; 88(5): F432 - F433. [Abstract] [Full Text] [PDF]

				P. J. Sharek, R. Baker, F. Litman, J. Kaempf, K. Burch, E. Schwarz, S. Sun, and N. R. Payne Evaluation and Development of Potentially Better Practices to Prevent Chronic Lung Disease and Reduce Lung Injury in Neonates Pediatrics, April 1, 2003; 111(4): e426 - 431. [Abstract] [Full Text] [PDF]

				E. Kajantie, L. Dunkel, U. Turpeinen, U.-H. Stenman, P. J. Wood, M. Nuutila, and S. Andersson Placental 11{beta}-Hydroxysteroid Dehydrogenase-2 and Fetal Cortisol/Cortisone Shuttle in Small Preterm Infants J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 493 - 500. [Abstract] [Full Text] [PDF]

				T. Saaresranta and O. Polo Hormones and Breathing Chest, December 1, 2002; 122(6): 2165 - 2182. [Abstract] [Full Text] [PDF]

				W. D. Engle and J. L. LeFlore Hypotension in the Neonate NeoReviews, August 1, 2002; 3(8): e157 - 162. [Full Text] [PDF]

				R. J. Bolt, M. M. van Weissenbruch, C. Popp-Snijders, C. G. J. Sweep, H. N. Lafeber, and H. A. Delemarre-van de Waal Fetal Growth and the Function of the Adrenal Cortex in Preterm Infants J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1194 - 1199. [Abstract] [Full Text] [PDF]

				B. A. Banks Postnatal Dexamethasone for Bronchopulmonary Dysplasia: A Systematic Review and Meta-analysis of 20 Years of Clinical Trials NeoReviews, February 1, 2002; 3(2): e24 - 34. [Full Text]

				The Vermont Oxford Network Steroid Study Group Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease Pediatrics, September 1, 2001; 108(3): 741 - 748. [Abstract] [Full Text] [PDF]

				M. Avent, D. Coile, and L. Mathai Neonatal Chronic Lung Disease Journal of Pharmacy Practice, June 1, 2001; 14(3): 181 - 206. [Abstract] [PDF]

				A. H. JOBE and E. BANCALARI Bronchopulmonary Dysplasia Am. J. Respir. Crit. Care Med., June 1, 2001; 163(7): 1723 - 1729. [Full Text] [PDF]

				K. J. Barrington Postnatal Steroids and Neurodevelopmental Outcomes: A Problem In the Making Pediatrics, June 1, 2001; 107(6): 1425 - 1426. [Full Text]

				I. Seri, R. Tan, and J. Evans Cardiovascular Effects of Hydrocortisone in Preterm Infants With Pressor-Resistant Hypotension Pediatrics, May 1, 2001; 107(5): 1070 - 1074. [Abstract] [Full Text]

				B. A. Banks, N. Stouffer, A. Cnaan, Y. Ning, J. D. Merrill, R. A. Ballard, P. L. Ballard, and the North American Thyrotropin-Releasing Hormone T Association of Plasma Cortisol and Chronic Lung Disease in Preterm Infants Pediatrics, March 1, 2001; 107(3): 494 - 498. [Abstract] [Full Text]

				B. Thébaud, T. Lacaze-Masmonteil, and K. Watterberg Postnatal Glucocorticoids in Very Preterm Infants: "The Good, the Bad, and the Ugly"? Pediatrics, February 1, 2001; 107(2): 413 - 415. [Full Text]

				A. R. Stark, W. A. Carlo, J. E. Tyson, L.-A. Papile, L. L. Wright, S. Shankaran, E. F. Donovan, W. Oh, C. R. Bauer, S. Saha, et al. Adverse Effects of Early Dexamethasone Treatment in Extremely-Low-Birth-Weight Infants N. Engl. J. Med., January 11, 2001; 344(2): 95 - 101. [Abstract] [Full Text] [PDF]

eLetters: